Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.
Six HIV-positive antiretroviral experienced patients initiating therapy with a regimen including lopinavir/ritonavir (400/100 mg twice per day) and indinavir (800 mg twice per day) underwent steady-state pharmacokinetic analysis. The AUC0-12 h of indinavir when combined with lopinavir/ritonavir was comparable with previously published data on indinavir/ritonavir 800/100 mg twice per day in HIV-infected individuals. However, lopinavir AUC0-12 h, Cmax, and C12 h were lower than previously reported in the absence of indinavir. The regimen was well tolerated, although 2 patients developed grade 3 hypertriglyceridemia. No patient discontinued the regimen because of indinavir-related urologic or retinoid-type adverse effects. Further study of the regimen with larger cohorts of patients is necessary.
Antoniou
Tony
T
St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. tantoniou@smh.toronto.on.ca
Tseng
Alice L
AL
van Heeswijk
Rolf P G
RP
Walker
Scott E
SE
Giguere
Pierre
P
Phillips
Elizabeth J
EJ
D000328:Adult; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D019469:Indinavir / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D061466:Lopinavir; D008297:Male; D008657:Metabolic Clearance Rate; D011744:Pyrimidinones / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019469:Indinavir